ACF Webinar Feb 8th, 12 EST Rivaroxaban w/wo Aspirin in Stable Cardiovascular Disease COMPASS Trial

Elaine WhalenElaine Whalen Member
edited January 2018 in My Groups & Collaboratives

Guest Author & Presenter: John Eikelboom, M.B., B.S.
Moderators: Jack Ansell, MD; Tracy Minichiello, MD;
Sara Vazquez, PharmD; Diane Wirth, ANP, CACP
The COMPASS Trial evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.

The webinar will focus on emerging evidence with the COMPASS Trial, including the sub-analysis on CAD and PAD. Sign up here:

Sign In or Register to comment.